Flowers
$12.00 – $45.99Price range: $12.00 through $45.99
Select options
This product has multiple variants. The options may be chosen on the product page
When it comes to medical marijuana, our statute does not address advertising (other than listing of prices). The regulations discuss only physical characteristics of alternative treatment centers and a prohibition on certain merchandising. As for industrial hemp, although the Hemp Farming Act enacted this past summer allows New Jersey licensees to grow, cultivate, and process hemp. We are still waiting on regulations setting the parameters of such activities, including advertising and marketing. That means we also do not have any rules for the advertisement of hemp-derived CBD products.
New Jersey’s proposed adult-use marijuana bill (S2703) included many of the advertising rules seen in other states. It may have health risks associated with marijuana use, such as impairment of concentration. The law also prohibits advertising in certain locations where minors are likely to be present or in a manner that appeals to minors
Despite a lack of cannabis-specific laws in the Garden State, you cannot ignore our general laws governing commercial conduct. Which applies equally to any business or industry. For instance, cannabis businesses always need to be wary of the Consumer Fraud Act (“CFA”). Prohibiting unconscionable commercial practices, deception, fraud, false pretense, false promise, misrepresentation, or the knowing, concealment, suppression, or omission of any material fact in connection with the sale or advertisement of any merchandise. New Jersey’s CFA is one of the strongest in the country. Violations of the CFA come with a heavy price – treble (triple) damages and attorneys’ fees to the successful plaintiff.
Additionally, federal law must always be a consideration. The Food and Drug Administration (“FDA”) continues to crack down on businesses that are marketing unproven medical claims. Recently, the FDA issued warning letters to 15 more companies that were advertising their CBD products in violation of the Food, Drug, and Cosmetic Act. The common theme of unlawful conduct was the companies touting the alleged therapeutic benefits of CBD. In addition, the FDA reiterated that it cannot yet conclude that CBD can be used safely in food as of now.
Despite not having laws focused on advertising and marketing in New Jersey, running afoul of federal law and general consumer laws is something cannabis businesses cannot afford to do.
Receiving an FDA warning letter is not merely a friendly reminder. The recipient has a limited timeframe to correct the problem and must submit to the FDA a plan of action. Thereafter, the FDA will follow up to ensure compliance with the warning letter. If violations persist, that can lead to fines, penalties, and administrative hearings.
Defending an administrative action or a consumer fraud lawsuit not only involves a mountain of legal fees. Consider the money and time revamping the company website, the monies spent on marketing materials that can no longer be used, and now the cost of new marketing materials.
No account yet?
Create an AccountYou must be 21 years of age or older to view page. Please verify your age to enter.
Your access is restricted because of your age.